Suppr超能文献

为重型或中间型地中海贫血患者进行脾切除术。

Splenectomy for people with thalassaemia major or intermedia.

作者信息

Sharma Akshay, Easow Mathew Manu, Puri Latika

机构信息

St Jude Children's Research Hospital, 262 Danny Thomas Place, MS 260, Memphis, Tennessee, USA, 38105.

出版信息

Cochrane Database Syst Rev. 2019 Sep 17;9(9):CD010517. doi: 10.1002/14651858.CD010517.pub3.

Abstract

BACKGROUND

Thalassaemia is a genetic disorder of the haemoglobin protein in red blood cells. It has been historically classified into thalassaemia minor, intermedia and major, depending on the genetic defect and severity of the disease. The clinical presentation of β-thalassaemia varies widely from a mild asymptomatic form in thalassaemia minor, to a severe disease in thalassaemia major where individuals are dependant on life-long blood transfusions. The hallmark of thalassaemia syndromes is the production of defective red blood cells that are removed by the spleen resulting in an enlarged hyperfunctioning spleen (splenomegaly). Removal of the spleen may thus prolong red blood cell survival by reducing the amount of red blood cells removed from circulation and may ultimately result in the reduced need for blood transfusions.

OBJECTIVES

To assess the efficacy and safety of splenectomy in people with β-thalassaemia major or intermedia.

SEARCH METHODS

We searched the Cochrane Cystic Fibrosis and Genetic Disorders Review Group's Haemoglobinopathies Trials Register, compiled from searches of electronic databases and the handsearching of journals and conference abstract books. We also searched online trial registries and the reference lists of relevant articles and reviews (27 July 2018).Date of the most recent search of the Group's trials register: 02 August 2019.

SELECTION CRITERIA

We included randomised controlled and quasi-randomised controlled studies of people of any age with thalassaemia major or intermedia, evaluating splenectomy in comparison to conservative treatment (transfusion therapy and iron chelation) or other forms of splenectomy compared to each other (laparoscopic, open, radio-frequency).

DATA COLLECTION AND ANALYSIS

Two authors independently selected and extracted data from the single included study using a customised data extraction form and assessed the risk of bias. The quality of the evidence was assessed using GRADE.

MAIN RESULTS

One study, including 28 participants was included in the review; the results were described, primarily, in a narrative manner. This study assessed the feasibility of splenectomy using a laparoscopic approach versus open surgery. Given the lack of detail regarding the study methods beyond randomisation, the overall risk of bias for this study was unclear. The study was carried out over a period of 3.5 years, with each participant followed up only until discharge (less than one week after the intervention); it did not assess the majority of the outcomes outlined in this review (including two of the three primary outcomes, frequency of transfusion and quality of life). A total of three serious post-operative adverse events (the review's third primary outcome) were reported in the laparoscopic splenectomy group (one case of atelectasis and two cases of bleeding), compared to two events of atelectasis in the open surgery group; however, there were no significant differences between the groups for either atelectasis, risk ratio (RR) 0.50 (95% confidence interval (CI) 0.05 to 4.90) or for bleeding, RR 5.00 (95% CI 0.26 to 95.61) (very low-quality evidence). In addition, the study also reported three serious cases of intra-operative bleeding in the laparoscopic group which mandated conversion to open surgery, although the difference between groups was not statistically significant, RR 7.00 (95% CI 0.39 to 124.14) (very low-quality evidence). These effect estimates are based on very small numbers and hence are unreliable and imprecise. From this small study, there appeared to be an advantage for the laparoscopic approach, in terms of post-operative hospital stay, although the group difference was not large (median difference of 1.5 days, P = 0.03).

AUTHORS' CONCLUSIONS: The review was unable to find good quality evidence, in the form of randomised controlled studies, regarding the efficacy of splenectomy for treating thalassaemia major or intermedia. The single included study provided little information about the efficacy of splenectomy, and compared open surgery and laparoscopic methods. Further studies need to evaluate the long-term effectiveness of splenectomy and the comparative advantages of surgical methods. Due to a lack of high quality evidence from randomised controlled studies, well-conducted observational studies may be used to answer this question.

摘要

背景

地中海贫血是一种红细胞中血红蛋白蛋白的遗传性疾病。根据遗传缺陷和疾病严重程度,其历史上被分为轻型地中海贫血、中间型地中海贫血和重型地中海贫血。β地中海贫血的临床表现差异很大,从轻型地中海贫血的轻度无症状形式,到重型地中海贫血的严重疾病,患者需要终身输血。地中海贫血综合征的标志是产生有缺陷的红细胞,这些红细胞会被脾脏清除,导致脾脏肿大、功能亢进(脾肿大)。因此,切除脾脏可能通过减少循环中被清除的红细胞数量来延长红细胞存活时间,并最终可能减少输血需求。

目的

评估脾切除术治疗重型或中间型β地中海贫血患者的疗效和安全性。

检索方法

我们检索了Cochrane囊性纤维化和遗传疾病综述小组的血红蛋白病试验注册库,该注册库通过检索电子数据库以及手工检索期刊和会议摘要书籍编制而成。我们还检索了在线试验注册库以及相关文章和综述的参考文献列表(2018年7月27日)。该小组试验注册库的最新检索日期:2019年8月2日。

选择标准

我们纳入了对任何年龄的重型或中间型地中海贫血患者进行的随机对照和半随机对照研究,评估脾切除术与保守治疗(输血治疗和铁螯合)相比的效果,或不同形式脾切除术(腹腔镜、开放、射频)之间相互比较的效果。

数据收集与分析

两位作者使用定制的数据提取表独立从纳入的单项研究中选择并提取数据,并评估偏倚风险。使用GRADE评估证据质量。

主要结果

本综述纳入了一项研究,包括28名参与者;结果主要以叙述方式描述。该研究评估了腹腔镜手术与开放手术进行脾切除术的可行性。鉴于随机分组以外的研究方法缺乏详细信息,该研究的总体偏倚风险尚不清楚。该研究为期3.5年,每位参与者仅随访至出院(干预后不到一周);它没有评估本综述中概述的大多数结局(包括三个主要结局中的两个,输血频率和生活质量)。腹腔镜脾切除术组共报告了3例严重术后不良事件(本综述的第三个主要结局)(1例肺不张和2例出血),开放手术组有2例肺不张事件;然而,两组在肺不张方面无显著差异,风险比(RR)为0.50(95%置信区间(CI)0.05至4.90),出血方面也无显著差异,RR为5.00(95%CI 0.26至95.61)(极低质量证据)。此外,该研究还报告了腹腔镜组3例术中严重出血病例,这些病例需要转为开放手术,尽管两组之间的差异无统计学意义,RR为7.00(95%CI 0.39至124.14)(极低质量证据)。这些效应估计基于非常小的样本量,因此不可靠且不精确。从这项小型研究来看,就术后住院时间而言,腹腔镜手术似乎有优势,尽管组间差异不大(中位数差异为1.5天,P = 0.03)。

作者结论

本综述未能找到以随机对照研究形式存在的关于脾切除术治疗重型或中间型地中海贫血疗效的高质量证据。纳入的单项研究几乎没有提供关于脾切除术疗效的信息,且比较了开放手术和腹腔镜手术方法。需要进一步研究评估脾切除术的长期有效性以及手术方法的比较优势。由于缺乏随机对照研究的高质量证据,可使用开展良好的观察性研究来回答这个问题。

相似文献

1
Splenectomy for people with thalassaemia major or intermedia.
Cochrane Database Syst Rev. 2019 Sep 17;9(9):CD010517. doi: 10.1002/14651858.CD010517.pub3.
2
Splenectomy for people with thalassaemia major or intermedia.
Cochrane Database Syst Rev. 2016 Jun 14(6):CD010517. doi: 10.1002/14651858.CD010517.pub2.
4
Hydroxyurea for reducing blood transfusion in non-transfusion dependent beta thalassaemias.
Cochrane Database Syst Rev. 2016 Oct 18;10(10):CD011579. doi: 10.1002/14651858.CD011579.pub2.
5
Interventions for improving adherence to iron chelation therapy in people with sickle cell disease or thalassaemia.
Cochrane Database Syst Rev. 2018 May 8;5(5):CD012349. doi: 10.1002/14651858.CD012349.pub2.
6
Growth hormone therapy for people with thalassaemia.
Cochrane Database Syst Rev. 2017 Sep 18;9(9):CD012284. doi: 10.1002/14651858.CD012284.pub2.
7
Calcium channel blockers for preventing cardiomyopathy due to iron overload in people with transfusion-dependent beta thalassaemia.
Cochrane Database Syst Rev. 2018 Jul 12;7(7):CD011626. doi: 10.1002/14651858.CD011626.pub2.
8
Growth hormone therapy for people with thalassaemia.
Cochrane Database Syst Rev. 2020 May 28;5(5):CD012284. doi: 10.1002/14651858.CD012284.pub3.
9
Calcium channel blockers for preventing cardiomyopathy due to iron overload in people with transfusion-dependent beta thalassaemia.
Cochrane Database Syst Rev. 2023 Nov 17;11(11):CD011626. doi: 10.1002/14651858.CD011626.pub3.
10
Hematopoietic stem cell transplantation for people with ß-thalassaemia major.
Cochrane Database Syst Rev. 2011 Oct 5(10):CD008708. doi: 10.1002/14651858.CD008708.pub2.

引用本文的文献

1
Assessment of health-related quality of life in transfusion dependent beta thalassemia.
Sci Rep. 2025 Sep 2;15(1):32267. doi: 10.1038/s41598-025-07728-6.
6
Human DNA Mutations and their Impact on Genetic Disorders.
Recent Pat Biotechnol. 2024;18(4):288-315. doi: 10.2174/0118722083255081231020055309.
8
Foetal haemoglobin inducers for reducing blood transfusion in non-transfusion-dependent beta-thalassaemias.
Cochrane Database Syst Rev. 2023 Jan 13;1(1):CD013767. doi: 10.1002/14651858.CD013767.pub2.
9
Luspatercept: A Review in Transfusion-Dependent Anaemia due to Myelodysplastic Syndromes or β-Thalassaemia.
Drugs. 2021 Jun;81(8):945-952. doi: 10.1007/s40265-021-01527-9. Epub 2021 May 10.
10
Hepatocellular carcinoma in adult thalassemia patients: an expert opinion based on current evidence.
BMC Gastroenterol. 2020 Aug 3;20(1):251. doi: 10.1186/s12876-020-01391-z.

本文引用的文献

1
Emerging Therapies.
Hematol Oncol Clin North Am. 2018 Apr;32(2):343-352. doi: 10.1016/j.hoc.2017.11.002. Epub 2017 Dec 15.
2
Clinical Classification, Screening and Diagnosis for Thalassemia.
Hematol Oncol Clin North Am. 2018 Apr;32(2):193-211. doi: 10.1016/j.hoc.2017.11.006.
3
Recommendations regarding splenectomy in hereditary hemolytic anemias.
Haematologica. 2017 Aug;102(8):1304-1313. doi: 10.3324/haematol.2016.161166. Epub 2017 May 26.
4
Splenectomy for people with thalassaemia major or intermedia.
Cochrane Database Syst Rev. 2016 Jun 14(6):CD010517. doi: 10.1002/14651858.CD010517.pub2.
5
Splenectomy for Children With Thalassemia: Total or Partial Splenectomy, Open or Laparoscopic Splenectomy.
J Pediatr Hematol Oncol. 2016 Jan;38(1):1-4. doi: 10.1097/MPH.0000000000000121.
6
Thalassemias.
Pediatr Clin North Am. 2013 Dec;60(6):1383-91. doi: 10.1016/j.pcl.2013.08.008. Epub 2013 Oct 4.
7
Non-transfusion-dependent thalassemias.
Haematologica. 2013 Jun;98(6):833-44. doi: 10.3324/haematol.2012.066845.
8
Effect of splenectomy on iron balance in patients with β-thalassemia major: a long-term follow-up.
Eur J Haematol. 2013 Jul;91(1):69-73. doi: 10.1111/ejh.12121. Epub 2013 May 24.
9
Treating iron overload in patients with non-transfusion-dependent thalassemia.
Am J Hematol. 2013 May;88(5):409-15. doi: 10.1002/ajh.23405. Epub 2013 Mar 8.
10
Advances in the treatment of alpha-thalassemia.
Blood Rev. 2012 Apr;26 Suppl 1:S31-4. doi: 10.1016/S0268-960X(12)70010-3.

文献AI研究员

20分钟写一篇综述,助力文献阅读效率提升50倍。

立即体验

用中文搜PubMed

大模型驱动的PubMed中文搜索引擎

马上搜索

文档翻译

学术文献翻译模型,支持多种主流文档格式。

立即体验